PTC Therapeutics, Inc. (PTCT)

PTC Therapeutics Revenue by Segment

Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020
Collaboration	986.54M	304.00K	-	-	-	100.03M	-	-
Collaboration Growth	-	-99.70%	-	-	-	99.85%	-	-
Net Product	576.77M	600.95M	601.31M	609.92M	651.30M	661.25M	633.70M	623.84M
Net Product Growth	-11.44%	-9.12%	-5.11%	-2.23%	9.84%	23.55%	20.33%	22.79%
Royalty	209.15M	203.86M	196.70M	185.51M	169.18M	168.86M	157.73M	140.48M
Royalty Growth	23.63%	20.73%	24.71%	32.05%	34.85%	48.74%	66.14%	86.96%
Manufacturing	-	-	-	5.00M	7.06M	7.69M	6.72M	4.35M
Manufacturing Growth	-	-	-	14.85%	255.08%	-	-	-

Revenue by Product

Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020
Translarna	322.70M	340.30M	321.50M	318.20M	344.30M	355.80M	336.40M	344.00M
Translarna Growth	-6.27%	-4.36%	-4.43%	-7.50%	6.10%	23.28%	11.21%	17.37%
Emflaza	197.20M	206.70M	224.10M	239.60M	258.00M	255.10M	245.80M	233.20M
Emflaza Growth	-23.57%	-18.97%	-8.83%	2.74%	15.02%	16.86%	18.34%	16.60%

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.